Shots:

• Purdue to receive one-time payment from Eisai- while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and commercialization rights for lemborexant- previously held by Purdue in the deal of Aug’15
• The termination enables Purdue to focus on oncology- non-opioid pain & CNS programs. In Aug’15- Eisai granted WW development & commercialization rights of lemborexant to Purdue and shared clinical study & development costs
• Lemborexant is a dual orexin receptor antagonist used for insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer’s disease. The US FDA accepted its NDA application with PDUFA date on Dec 27- 2019

Ref: Purdue Pharma | Image: Twitter